For cell therapy manufacturers such as Kite Pharma where every product is made for a single patient, labeling becomes a ...

The recent news of Novo Nordisk’s nearly 10% stock decline – currently -6.6% – following disappointing Alzheimer’s trial results for its Ozempic pill highlights the volatility in pharmaceutical stocks ...

Jefferies’ latest pharma report highlights India’s top drugmakers with fresh ‘Buy’ calls. The brokerage firm Nuvama has identified seven stocks in the pharma sector that it believes are better placed ...

U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S.

ISLAMABAD: Some of the top global pharmaceutical companies have left Pakistan due to a revision of their business plan, rupee depreciation and due to competition with the local pharmaceutical ...

In a closely watched case, the U.S. solicitor general has urged the Supreme Court to review a controversy over so-called skinny labels for medicines, ...

Atea Pharmaceuticals (AVIR) offers a late-stage, best-in-class HCV cure, with significant upside, currently trading below cash. BEM/RZR combines advantages of current first-line HCV therapies — single ...

Sun Pharmaceutical Industries Limited announced the US Food and Drug Administration (FDA) approved an updated label for Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic CSCC or ...

As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition, offering a balance of durable clinical responses and acceptable ...

Exactly a month after it announced the removal of black box warning labels on estrogen therapy products used in menopause, the Food and Drugs ...

When the FDA reworked the prescribing information for Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy Elevidys earlier this month, the company touted a plan to study a regimen ...

With both a label expansion and a conversion to a full approval, Eli Lilly has earned the FDA’s go-ahead to act on the initial promise it saw with its BTK inhibitor Jaypirca (pirtobrutinib). Just ...